SNSS - Sunesis Pharmaceuticals Inc. (SNSS) Interim CEO Dayton Misfeldt on Q2 2019 Results - Earnings Call Transcript
Sunesis Pharmaceuticals, Inc. (SNSS)
Q2 2019 Earnings Conference Call
August 07, 2019 04:30 PM ET
Company Participants
Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development
Dayton Misfeldt - Interim Chief Executive Officer
Judy Fox - Chief Scientific Officer
Par Hyare - Senior Vice President Commercial
Deepali Suri - Vice President, Clinical Operations
Conference Call Participants
Marc Frahm - Colin
Hartaj Singh - Oppenheimer
Jim Birchenough - Wells Fargo Securities
Yanan Zhu - Wells Fargo Securities
Presentation
Operator
Good afternoon, ladies and gentlemen, and welcome to the Sunesis Pharmaceuticals Second Quarter 2019